Pfizer

BNTX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX

Retrieved on: 
Sunday, March 3, 2024

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 2, 2024

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against BioNTech SE (BNTX)

Retrieved on: 
Friday, March 1, 2024

On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.

Key Points: 
  • On this news, BioNTech’s stock price fell $13.81, or 7.5%, to close at $169.30 per share on August 8, 2022, thereby injuring investors.
  • On this news, BioNTech’s stock price fell $4.60, or 3.6%, to close at $123.60 per share on March 27, 2023.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

GeoVax Reports 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024

ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.

Key Points: 
  • ET
    ATLANTA, GA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced its financial results and key operational accomplishments for the year ended December 31, 2023.
  • Results to date have demonstrated safety of this therapy and consistent reduction in treated tumors.
  • Cash Position: GeoVax reported cash balances of $6.5 million on December 31, 2023, as compared to $27.6 on December 31, 2022.
  • ET today, February 29, 2024, to review financial results and provide an update on corporate developments.

Kidney Month: 31 Day of Action to Equip and Empower People to Fight Kidney Disease

Retrieved on: 
Thursday, February 29, 2024

During Kidney Month, AKF calls on members of the kidney community and the general public to join in solidarity in support of everyone affected by kidney disease.

Key Points: 
  • During Kidney Month, AKF calls on members of the kidney community and the general public to join in solidarity in support of everyone affected by kidney disease.
  • One of the hallmarks of Kidney Month at AKF is Kidney Action Week , which will be held March 18-22.
  • This free, virtual event will bring together patients, nephrologists, renal dieticians, caregivers and other kidney experts for a weeklong series of sessions about a variety of topics related to kidney disease, including dialysis, kidney disease prevention, kidney-friendly eating, transplant, innovations in kidney disease and more.
  • In addition, people with kidney disease have a higher chance of developing other health problems, such as heart disease.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTech SE of Class Action Lawsuit and Upcoming Deadlines – BNTX

Retrieved on: 
Wednesday, February 28, 2024

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • BioNTech is a biotechnology company that develops and commercializes immunotherapies for cancer and other infectious diseases.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important March 12 Deadline in Securities Class Action – BNTX

Retrieved on: 
Wednesday, February 28, 2024

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq.
  • If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Retrieved on: 
Wednesday, February 28, 2024

SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.

Key Points: 
  • SPR206 is a novel, intravenously (IV) administered next-generation polymyxin antibiotic for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by MDR Gram-negative bacterial infections.
  • "Clearance of this IND is an important milestone in our SPR206 development program, as we prepare to advance this drug candidate into a Phase 2 trial in HABP/VABP," said Kamal Hamed, Spero’s Chief Medical Officer.
  • "HABP/VABP are serious infections associated with high mortality and substantial morbidity, and their management has been complicated by the increasing prevalence of difficult-to-treat and MDR Gram-negative pathogens.
  • SPR206 is subject to a license agreement with Pfizer Inc., which was made alongside Pfizer’s $40 million equity investment in Spero, previously announced in June 2021.

Nicox Appoints Experienced Biotech Executive Gavin Spencer as CEO

Retrieved on: 
Wednesday, February 28, 2024

Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.

Key Points: 
  • Gavin Spencer was most recently Executive Vice-President, Chief Business Officer & Head of Corporate Development at Nicox.
  • “I am delighted to welcome Gavin Spencer to his new role as CEO of Nicox.
  • Gavin brings exhaustive industry experience, particularly related to strategic partnership agreements and financing.
  • During his time with Nicox, since 2005, Gavin Spencer has had a key role in building and managing Nicox’s partnerships, including closing agreements with Pfizer, Bausch + Lomb, VISUfarma and Ocumension Therapeutics.

OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Retrieved on: 
Tuesday, February 27, 2024

MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.

Key Points: 
  • MIAMI, Feb. 27, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2023.
    Business highlights from the fourth quarter and subsequent weeks included the following:
    ModeX advanced its antiviral and immune-oncology product pipeline.
  • Operating loss was $16.0 million in the fourth quarter of 2023 compared with $22.0 million in the fourth quarter of 2022.
  • Total costs and expenses for the fourth quarter of 2023 were $166.4 million compared with $162.5 million in the fourth quarter of 2022.
  • Operating loss for the fourth quarter of 2023 was $69.1 million compared with an operating loss of $55.3 million for the 2022 quarter.